Position statements

Breakthrough therapies and the New Zealand Early Access to Medicines Scheme

It is highly unusual for the Cancer Society to get involved in any national debate around the funding of particular cancer drugs. However, in the case of the new immunotherapies for melanoma, we have made an exception for reasons of equity, evidence and deep concerns about decision processes.